KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Retained Earnings (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Retained Earnings data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.07% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 100.07%, while the annual FY2025 figure was $1.4 million, 100.07% up from the prior year.
  • Retained Earnings reached $1.4 million in Q4 2025 per ACAD's latest filing, up from $989000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.4 million in Q4 2025 and bottomed at -$2.5 billion in Q3 2023.
  • Average Retained Earnings over 5 years is -$1.3 billion, with a median of -$2.1 billion recorded in 2021.
  • Peak YoY movement for Retained Earnings: tumbled 232782500.0% in 2022, then soared 219.76% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$2.2 billion in 2021, then fell by 10.03% to -$2.4 billion in 2022, then fell by 2.59% to -$2.4 billion in 2023, then increased by 9.32% to -$2.2 billion in 2024, then skyrocketed by 100.07% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $1.4 million in Q4 2025, $989000.0 in Q3 2025, and $406000.0 in Q2 2025.